CODE 1 - RESTRICTED TO MILD-MODERATE DEMENTIA FOR
CODE 1 - MAX (# 45 TABS/FILL), (3 FILLS/75 DAYS)
CODE 1 - MAX (# 10 PATCHES/FILL), (3 FILLS/75 DAYS)
CODE 1 - MAX (# 10 PATCHES/FILL), (3 FILLS/75 DAYS)
CODE 1 - MAX (# 10 PATCHES/FILL), (3 FILLS/75 DAYS)
CODE 1 - MAX (# 10 PATCHES/FILL), (3 FILLS/75 DAYS)
CODE 1 - Restricted to a TOTAL of 90 tablets per 30 day period of Norco TAB
CODE 1 - Restricted to a TOTAL of 90 tablets per 30 day period of Norco TAB
CODE 1 - MAX (#90 TABS/FILL), (3 FILLS/75 DAYS)
CODE 1 - MAX (#120 TABS/FILL), (3 FILLS/75 DAYS)
MAX 10 MG (#240 TABS/FILL), (3 FILLS/75 DAYS)
CODE 1 - MAX (#90/FILL), (3 FILLS/75 DAYS)
Restricted to patients receiving new prescriptions from Spine
Clinic/Infusion Center or maintained on this medication.
CODE 1 - MAX (#30 TABS/FILL), (3 FILLS/ 75 DAYS)
CODE 1 - Max (#30/FILL), (3 FILLS/75 days)
CODE 1 - No max tab restriction if Rx written by pschiatry or neurology. All TAB
other prescribers restricted to max 90 tabs per 30 day period.
CODE 1 - MAX (#30 TABS/FILL), (3 FILLS/ 75 DAYS)
CODE 1 - MAX (#30 TABS/FILL), (3 FILLS/ 75 DAYS)
CODE 1 - Max (#30/FILL), (3 FILLS/75 days)
Antibiotic - Cephalosporin, 1st Gen Cephalexin
Antibiotic - Cephalosporin, 1st Gen Cephalexin
Antibiotic - Cephalosporin, 1st Gen Cephalexin
Antibiotic - Cephalosporin, 1st Gen Cephalexin
Antibiotic - Cephalosporin, 1st Gen Cephalexin
Antibiotic - Cephalosporin, 1st Gen Cephalexin
Antibiotic - Cephalosporin, 3rd Gen Cefdinir
CAP 300 mg, SUSP 125 mg/mL, SUSP 250 mg/5 mL
CODE 1 - MAX (#10 TABS/FILL), (2 FILLS/30 DAYS)
CODE 1 - MAX (#10 TABS/FILL), (2 FILLS/30 DAYS)
CODE 1 - MAX (#10 TABS/FILL), (2 FILLS/30 DAYS)
CODE 1 - MAX (# 8 TABS/FILL), (2 FILLS/ 30 DAYS)
CODE 1 - MAX (# 30 TABS/FILL), (2 FILLS/ 30 DAYS)
CODE 1 - MAX (# 30 TABS/FILL), (2 FILLS/ 30 DAYS)
CODE 1 - MAX (#20 TABS/FILL), (2 FILLS/30 DAYS)
CODE 1 - MAX (# 30 TABS/FILL), ( 2 FILLS/ 30 DAYS)
Trimethoprim/Sulfamethoxazole; Co- Septra, Septra DS, Bactrim, Bactrim
Trimethoprim/Sulfamethoxazole; Co- Septra, Septra DS, Bactrim, Bactrim
Trimethoprim/Sulfamethoxazole; Co- Septra, Septra DS, Bactrim, Bactrim
Trimethoprim/Sulfamethoxazole; Co- Septra, Septra DS, Bactrim, Bactrim
Antibiotic - Sulfonamide/Macrolide Erythromycin/Sulfisoxazole
Antibiotic - Sulfonamide/Macrolide Erythromycin/Sulfisoxazole
Antibiotic - Sulfonamide/Macrolide Erythromycin/Sulfisoxazole
TAB 150mg, 300mg, 600 mgSUSP 60 mg/mL (250 mL)
TAB (SR) 100 mg, 150 mgTAB (XL) 150 mg, 300 mg
TAB (ER) 37.5 mg, (ER) 75 mg, (ER) 150 mg
Lantus will be dispensed in place of Levemir per P&T autosubstitution
HUMALOG WILL BE DISPENSED IN PLACE OF APIDRA OR NOVOLOG INJ
NOVOLIN R WILL BE DISPENSED IN PLACEOF HUMULIN R PER P&T INJ
NOVOLIN 70/30 WILL BE DISPENSED IN PLACE OF HUMULIN 70/30
NOVOLIN N WILL BE DISPENSED IN PLACE OF HUMULIN N PER P&T INJ
CODE 1 - Restricted to H. pylori treatment
(FOR PTS WHO CANNOT TOLERATE PO, CANNOT HAVE NG TUBE,
RESTRICTED TO TREATMENT OF ANOREXIA ASSOCIATED W/ WT
LOSS IN AIDS PATIENTS AND ONCOLOGY PATIENTS.
CODE 1 - AIDS AND AIDS RELATED CONDITIONS
CODE 1 - AIDS AND AIDS RELATED CONDITIONS
RESTRICTED TO ONCHYMYCOSIS FOR 12 WEEKS OF THERAPY,
AND MUST HAVE LIVER FUNCTION TESTS WITHIN NORMAL LIMITS.
TAB 10 mg/10 mg, 20 mg/10 mg, 40 mg/10 mg
2nd LINE AGENT AFTER FAILURE ON DOXAZOSIN
2nd line agent after DMARDs and TNF blockersPatient Assistance Program Available
CODE 1 - Only for use in treatment of cancer. PAP avail.
Patient assistance program available.
RESTRICTED TO INFUSION CENTER. PAP available.
Patient assistance program available.
Patient assistance program available.
Patient assistance program available.
CODE 1 - RESTRICTED TO INFUSION CENTER. PAP avail.
Patient assistance program available.
Patient assistance program available.
Patient assistance program available.
Patient assistance program available.
Patient assistance program available.
Patient assistance program available.
Patient assistance program available.
Patient assistance program available.
Antiretroviral, Cellular Chemokine Maraviroc
CODE 1 - Age 16 years and older infected with only detectable CCR5-
Antiretroviral, Non-Nucleoside RTI Delavirdine
Antiretroviral, Non-Nucleoside RTI Efavirenz
Antiretroviral, Non-Nucleoside RTI Efavirenz/Emtricitabine/Tenofovir
Antiretroviral, Non-Nucleoside RTI Emtricitabine/Rilpivirine/Tenofovir
Antiretroviral, Non-Nucleoside RTI Etravirine
Antiretroviral, Non-Nucleoside RTI Nevirapine
Antiretroviral, Non-Nucleoside RTI Rilpivirine
CAP, delayed release, enteric coated 125 mg, 200 mg, 250 mg, 400 mg
CODE 1 - HIV or Chronic Hepatitis B Virus infection
TAB 75 mg, 150 mg, 300 mg, 400 mg, 600 mg
Anti-Ulcer/Dyspepsia - H2 blocker Famotidine
Anti-Ulcer/Dyspepsia - H2 blocker Famotidine
Anti-Ulcer/Dyspepsia - H2 blocker Famotidine
CODE 1 - AIDS AND AIDS RELATED CONDITIONS
CODE 1: AGE > 65 YEARS WITH INTERMITTENT CLAUDICATION
ORCODE 1: DIABETIC WITH INTERMITTENT CLAUDICATION
CODE 1: AGE > 65 YEARS WITH INTERMITTENT CLAUDICATION
ORCODE 1: DIABETIC WITH INTERMITTENT CLAUDICATION
mL, 40 mg/0.4 mLINJ (SYRINGE) 60 mg/0.6 mLINJ (SYRINGE) 80 mg/0.8 mL, 100 mg /1 mLINJ (SYRINGE) 120 mg/0.8 mL, 150 mg /1 mL
CODE 1 - DX OTHER THAN CONTRACEPTION AND DERMATOLOGIC TAB 3 mg/30 mcg (# 28)CONDITIONS
CODE 1 - DX OTHER THAN CONTRACEPTION AND DERMATOLOGIC TAB
CODE 1 - DX OTHER THAN CONTRACEPTION AND DERMATOLOGIC TAB 0.15 mg/30 mcg (# 84) CONDITIONS
CODE 1 - DX OTHER THAN CONTRACEPTION AND DERMATOLOGIC PATCH 6 mg/0.75 mgCONDITIONSMax: 9 Patches/75 days
CODE 1 - DX OTHER THAN CONTRACEPTION AND DERMATOLOGIC TAB
CODE 1 - DX OTHER THAN CONTRACEPTION AND DERMATOLOGIC TAB
CODE 1 - DX OTHER THAN CONTRACEPTION AND DERMATOLOGIC TAB
CODE 1 - DX OTHER THAN CONTRACEPTION AND DERMATOLOGIC TAB
CODE 1 - DX OTHER THAN CONTRACEPTION AND DERMATOLOGIC TAB
CODE 1 - DX OTHER THAN CONTRACEPTION AND DERMATOLOGIC TAB
CODE 1 - DX OTHER THAN CONTRACEPTION AND DERMATOLOGIC TAB
CODE 1 - DX OTHER THAN CONTRACEPTION AND DERMATOLOGIC TAB
CODE 1 - Restricted to patients already using Accu-Chek Aviva
Restricted to patients already using Accu-Chek Aviva glucometer.
CODE 1 - END STAGE RENAL DISEASE ON DIALYSIS
CODE 1 - END STAGE RENAL DISEASE ON DIALYSIS
Ergot Derivative, Anti-Parkinsonian Bromocriptine
TAB 0.3 mg, 0.45 mg, 0.625 mg, 0.9 mg, 1.25 mg, INJ 5 mg/mL (5 mL) vial
Estrogen Derivative - Combination Estrogen/Medroxyprogesterone
TAB 0.625 mg/2.5 mg, 0.625 mg/5 mg, 0.3 mg/1.5 mg (# 28)
CODE 1 - MAX (# 20 SYRINGES/FILL), (2 FILLS/ YR)
INJ (SYRINGE) 30 mg/0.3 mL, 40 mg/0.4 mLINJ (SYRINGE) 60 mg/0.6 mLINJ (SYRINGE) 80 mg/0.8 mL, 100 mg /1 mLINJ (SYRINGE) 120 mg/0.8 mL, 150 mg /1 mL
CODE 1 - MAX (# 9 TABS/MONTH) or MAX (#6 INJ/MONTH)
MAXIMUM #18/MONTH - PER MANUFACTURER RECOMMENDATION
CODE 1 - MAX (# 9 TABS/MONTH) or MAX (#6 INJ/MONTH)
MAXIMUM #18/MONTH - PER MANUFACTURER RECOMMENDATION
CODE 1 - MAX (# 9 TABS/MONTH) or MAX (#6 INJ/MONTH)
MAXIMUM #18/MONTH - PER MANUFACTURER RECOMMENDATION
CODE 1 - MAX (# 9 TABS/MONTH) or MAX (#6 INJ/MONTH)
MAXIMUM #18/MONTH - PER MANUFACTURER RECOMMENDATION
CODE 1 - MAX (# 9 TABS/MONTH) or MAX (#6 INJ/MONTH)
MAXIMUM #18/MONTH - PER MANUFACTURER RECOMMENDATION
CODE 1 - Restricted to treatment of pulmonary hypertension.
MDI 40 mcg.INH (8.7 g)MDI 80 mcg/INH (8.7 g)
MDI 45 mcg/21mcg, 115 mcg/21mcg, 230 mcg/21mcg
POWDER for INH 100 mcg/50 mcg (#60)POWDER for INH 250 mcg/50 mcg (#60)POWDER for INH 500 mcg/50 mcg (#60)
Restricted to dermatology or senior residents/attendings.
mgPATCH: 0.1 mg, 0.2 mg, 0.4 mg, 0.6 mg/hr
CODE 1 - MAX (# 2 INJECTORS/FILL), (2 FILLS/YR)
CODE 1 - MAX (# 2 INJECTORS/FILL), (2 FILLS/YR)
CODE 1 - Restricted to patients with one of the following conditions:
1) Post UA/NSTEMI with or without a stent for a maximum of 12 months of therapy 2) Post UA/NSTEMI/stroke with or without a stent when aspirin is contraindicated or not tolerated for an indefinite period of time3) Other conditions require a TAR
ISSN 2176-1213 - Semin. de IC. da UFPA, Belém, v. 22, n.1, 2011 EPIDEMIOLOGIA MOLECULAR DO HIV-1, DE ACORDO COM O GENE DA PROTEASE, EM MULHERES GRÁVIDAS, PORTADORAS DO HIV-1, DA CIDADE DE BELÉM, PARÁ. Gabriel Nobre de ANDRADE (Bolsista PIBIC/CNPq) – gabriel_nobre_andrade@hotmail.com Curso de Medicina, Faculdade de Medicina, Instituto de Ciências da Saúde. Prof. Dra. Marlu
Pharmacocinétique oculaire Pharmacologie oculaire (du 27 septembre au 29 septembre et du 6 novembre au 7 novembre 2006 ) 1ERE JOURNEE : MERCREDI 27 SEPTEMBRE 2006 MATIN 9 h 00 : ACCUEIL et Introduction : présentation et organisation du DIU Voies d’administration et pharmacocinétique oculaire 9 h 30 - 11 h 15 ⇒ Francine Behar-Cohen • Voie orale, IV, insti